{"id":"femcon-fe","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Breast tenderness"},{"rate":null,"effect":"Breakthrough bleeding"},{"rate":null,"effect":"Mood changes"},{"rate":"3-4 per 10,000 woman-years","effect":"Venous thromboembolism"}]},"_chembl":{"chemblId":"CHEMBL2106640","moleculeType":"Small molecule","molecularWeight":"555.00"},"_dailymed":{"setId":"8df6c027-eb7e-4f8d-9f06-61da861b660c","title":"FEMCON FE (NORETHINDRONE AND ETHINYL ESTRADIOL, AND FERROUS FUMARATE) KIT [PHYSICIANS TOTAL CARE, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The hormonal components work by inhibiting the luteinizing hormone (LH) surge needed for ovulation and by thickening cervical mucus to impede sperm penetration. The ferrous fumarate (iron) supplement is included in the placebo pills to maintain iron levels during the menstrual cycle and reduce the risk of iron-deficiency anemia in women taking oral contraceptives.","oneSentence":"FEMCON Fe is an oral contraceptive that prevents pregnancy by suppressing ovulation through a combination of ethinyl estradiol and norethindrone, while the ferrous fumarate component replaces iron lost during menstruation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T06:02:29.632Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception (prevention of pregnancy)"},{"name":"Regulation of menstrual cycle"}]},"trialDetails":[{"nctId":"NCT01344369","phase":"PHASE1","title":"Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2008-08","conditions":"Healthy","enrollment":36},{"nctId":"NCT01340625","phase":"PHASE1","title":"Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2006-12","conditions":"Bioequivalence","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ovcon® 35 Fe","norethindrone/ethinyl estradiol (generic name)"],"phase":"marketed","status":"active","brandName":"FEMCON® Fe","genericName":"FEMCON® Fe","companyName":"Teva Pharmaceuticals USA","companyId":"teva-pharmaceuticals-usa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FEMCON Fe is an oral contraceptive that prevents pregnancy by suppressing ovulation through a combination of ethinyl estradiol and norethindrone, while the ferrous fumarate component replaces iron lost during menstruation. Used for Contraception (prevention of pregnancy), Regulation of menstrual cycle.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}